深度测序揭示尼日利亚一线抗逆转录病毒方案失败后HIV-1亚型广泛变异及耐药
研究对尼日利亚101例一线ART失败并换用二线治疗者的失败样本进行HIV-1全基因组深度测序,分析≥2%频率的耐药突变。结果显示61%检出胸苷类似物突变,92%检出其他核心NRTI突变,99%检出NNRTI突变;K65R在CRF02_AG较G亚型更常见(33% vs 7%,P=0.002),≥3个TAM在G较CRF02_AG更常见(52% vs 24%,P=0.004);81%预测对多拉韦林、依曲韦林或利匹韦林至少一种存在交叉耐药。
要点
- 一线ART失败者中NNRTI突变检出率99%,核心NRTI突变92%,TAM 61%。
- K65R在CRF02_AG 33% vs G亚型7%(P=0.002)。
- ≥3个TAM在G亚型52% vs CRF02_AG 24%(P=0.004)。
核心结论
- 西非HIV-1亚型感染者在一线ART失败后已积累广泛耐药,深度测序显著提高耐药相关突变检出,考虑新一代NNRTI时应谨慎。
研究设计与样本
- 从尼日利亚HIV感染者队列中选取一线ART失败并换用二线治疗的参与者,对失败样本用Illumina MiSeq进行HIV-1全基因组测序,分析≥2%频率的突变并按亚型比较。
主要发现
- 共获得101例参与者的HIV-1序列,65%为女性,中位年龄30岁,中位奈韦拉平或依非韦伦为基础ART时间32.9个月。
- 胸苷类似物突变检出率61%,其他核心NRTI突变92%,NNRTI突变99%;少数变异(<20%频率)占所有突变的18%。
- K65R在CRF02_AG较G亚型更常见(33% vs 7%,P=0.002);≥3个TAM在G较CRF02_AG更常见(52% vs 24%,P=0.004)。
- G亚型病毒还含有更多RT切割位点突变;81%的参与者预测对多拉韦林、依曲韦林或利匹韦林至少一种存在交叉耐药。
临床怎么用
- 作者认为在此背景下考虑新一代NNRTI药物时应谨慎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep sequencing could improve understanding of HIV treatment failure and viral population dynamics. However, this tool is often inaccessible in low- and middle-income countries. OBJECTIVES: To determine the genetic patterns of resistance emerging in West African HIV-1 subtypes during first-line virological failure, and the implications for future antiretroviral options. PATIENTS AND METHODS: Participants were selected from a Nigerian cohort of people living with HIV who had failed first-line ART and subsequently switched to second-line therapy. Whole HIV-1 genome sequences were generated from first-line virological failure samples with Illumina MiSeq. Mutations detected at ≥2% frequency were analysed and compared by subtype. RESULTS: HIV-1 sequences were obtained from 101 participants (65% female, median age 30 years, median 32.9 months of nevirapine- or efavirenz-based ART). Thymidine analogue mutations (TAMs) were detected in 61%, other core NRTI mutations in 92% and NNRTI mutations in 99%. Minority variants (<20% frequency) comprised 18% of all mutations. K65R was more prevalent in CRF02_AG than G subtypes (33% versus 7%; P = 0.002), and ≥3 TAMs were more common in G than CRF02_AG (52% versus 24%; P = 0.004). Subtype G viruses also contained more RT cleavage site mutations. Cross-resistance to at least one of the newer NNRTIs, doravirine, etravirine or rilpivirine, was predicted in 81% of participants. CONCLUSIONS: Extensive drug resistance had accumulated in people with West African HIV-1 subtypes, prior to second-line ART. Deep sequencing significantly increased the detection of resistance-associated mutations. Caution should be used if considering newer-generation NNRTI agents in this setting.
引用
- El Bouzidi K, Datir RP, Kwaghe V, et al. Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. J Antimicrob Chemother. 2022. PMID: 34741609. doi:10.1093/jac/dkab385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。